Skip to main
  1. Stocks
  2. Assembly Biosciences
  3. Forecast
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is attractive because it combines a de-risked balance sheet with meaningful pipeline expansion, ending 2Q26 with $320.4 million in cash and investments and expected funding into 2029, including the first $75 million Gilead collaboration extension payment due in 4Q26. Its lead ABI-6250 program now has two shots on goal, with a Phase 2 HDV trial expected by year-end 2026 and a new Phase 2 basket trial in PBC and PSC anticipated in 1Q27, while EASL 2026 data showed a four-day half-life, about seven-fold accumulation, and no pruritus despite dose-dependent bile-acid increases. The Gilead-selected GS-1179 program also gains optionality in recurrent genital herpes and potentially HIV PrEP, and the company’s model assigns a 70% approval probability to ABI-6250 and 70% to ABI-5366, supporting a favorable long-term fundamental view.

Bears say

Assembly Biosciences is viewed negatively because, despite $226.6M in cash at the end 1Q 2026 and the May 2026 offering that raised about $115M gross, the company still appears dependent on external financing before reaching sustainable profitability. Management’s cash runway into 2028 excludes possible GILD payments and warrant exercises, while profitability is not expected on a continuing basis until 2032, implying likely dilution from another capital raise. The valuation also remains highly exposed to clinical and commercial execution risk for ABI-5366, ABI-1179, and ABI-6250, as any delays, reimbursement issues, or weak commercialization could materially reduce sales potential.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction

Get the latest Assembly Biosciences (ASMB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Assembly Biosciences (ASMB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction

Get the latest Assembly Biosciences (ASMB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Assembly Biosciences (ASMB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ASMB stock data and trends